New Clinical Trial Compares SGLT2i vs. GLP-1RA for Diabetes Heart & Kidney Health
Background
Patients with Type 2 Diabetes (T2D) often face severe complications, including Atherosclerotic Cardiovascular Disease (ASCVD), where plaque builds up in arteries, and diabetic kidney disease. These conditions significantly increase the risk of heart attacks, strokes, and kidney failure. While both sodium-glucose cotransporter-2 inhibitors (SGLT2i) and glucagon-like peptide-1 receptor agonists (GLP-1RA) have shown benefits for T2D patients with cardiovascular and kidney issues, there is a critical need to directly compare their effectiveness in preventing combined cardiovascular, kidney, and death events in a real-world setting.
Results
As a recruiting clinical trial (NCT ID: NCT05390892), PRECIDENTD has not yet reported findings. However, its primary objective is to determine which treatment strategy, SGLT2i or GLP-1RA, is superior in reducing the total number of adverse events. The trial will meticulously count all occurrences of myocardial infarction (heart attack), stroke, arterial revascularization, hospitalization for heart failure, development of end-stage kidney disease, kidney transplantation, and mortality. This comprehensive approach will provide robust data on the comparative efficacy of these two powerful drug classes. The study aims to identify if one treatment significantly lowers the total burden of cardiovascular, kidney, and death events more effectively than the other in 6,000 high-risk T2D patients.
Why It Matters
This large-scale, pragmatic trial is crucial because it directly compares two leading therapeutic strategies for Type 2 Diabetes patients at high risk for cardiovascular and kidney complications. The findings could profoundly impact clinical guidelines for managing these patients, potentially leading to a preferred first-line treatment approach. If one class demonstrates superior outcomes, it could revolutionize how doctors prescribe medications to prevent heart attacks, strokes, and kidney failure in millions of T2D patients worldwide. The results, expected by 2029, will inform future treatment algorithms and potentially guide the development of new combination therapies.